Tissue engineering as a platform for controlled release of therapeutic agents: implantation of microencapsulated dopamine producing cells in the brains of rats.
Tissue engineering can lead to novel controlled release devices and controlled release strategies (e.g., of growth factors) can enhance the performance of tissue engineered constructs. There are however a number of technical challenges that must be overcome before these goals can be realized. The apparently 'simple' challenge of implanting the device (e.g., capsules) in the optimal site must be met. In addition, adequate nutrient supply to the capsules is required to maintain cell viability. To illustrate this problem we describe a guide and delivery cannula technique to provide reliable and reproducible delivery of up to 120 PC12 cell containing capsules into the caudate putamen (CPu). Microencapsulation of mammalian cells is potentially a powerful means of delivering therapeutically important molecules such as insulin. It can also have numerous applications as a platform for gene therapy. However, realizing this potential has been more difficult than first anticipated.
Vallbacka
J J
JJ
Institute for Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada M5S 3G9.
Nobrega
J N
JN
Sefton
M V
MV
D000818:Animals; D001921:Brain / Q000502:physiology*; D017690:Cell Transplantation / Q000379:methods*; D003692:Delayed-Action Preparations / Q000737:chemistry*; D004298:Dopamine / Q000096:biosynthesis*; D004339:Drug Compounding; D007150:Immunohistochemistry; D008297:Male; D016716:PC12 Cells; D051381:Rats; D017207:Rats, Sprague-Dawley; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D003692:Delayed-Action Preparations; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine